What is Localized Scleroderma Market?
It is estimated that up to three in every 100,000 people are diagnosed with localized scleroderma every year. This is more common in women compared to men. Localized scleroderma is characterized by the thickening of the skin from excessive collagen deposits, which lead to the appearance of thick, hard patches. It can be divided into two groups depending on the shape and area of skin affected, morphea and linear scleroderma. The morphea is characterized by thick, hard patches of skin that are white or yellow, and ringed with a purplish halo that may itch but is usually not painful and in linear scleroderma, there are thickened streaks of skin rather than patches, which more commonly extend deep into the skin.
The market study is being classified by Type (Morphea and Linear Scleroderma) and major geographies with country level break-up.
Actelion Pharmaceuticals, Inc. (Switzerland), Boehringer Ingelheim (Germany), Bayer AG (Germany), Cytori Therapeutics, Inc. (United States), Cumberland Pharmaceuticals Inc. (United States), Gilead Sciences, Inc. (United States), Pfizer Inc. (United States), Active Biotech AB (Sweden), BioLineRx, Ltd. (Israel) and Bristol-Myers Squibb Company (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are GenKyoTex SA (France) and Corbus Pharmaceuticals Holdings, Inc. (United States).
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Localized Scleroderma market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Localized Scleroderma market by Type, Application and Region.
On the basis of geography, the market of Localized Scleroderma has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increasing Incidences of Localized Scleroderma
- Increasing Number of Hospitals and Clinics
- Increasing Number of Research Activities
- Robust Increase in the Distribution Channels
- Less Awareness about Localized Scleroderma
- Growing Target Patient Population
- Growth in the Healthcare Industry
- Stringent Government Rules and Regulations
Key Target AudienceLocalized Scleroderma Treatment Providers, Distributors, Emerging Companies, Research Professionals and End-users
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase